Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy

xieruiqin

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: atorvastatin group; Drug: non-atorvastatin group

Study type: Interventional

Funder types: Other

Identifiers

NCT02776956

xierqdoctormd

Details and patient eligibility

About

A total of 120 patients with persistent atrial fibrillation (including continuous and long-standing persistent atrial fibrillation) and 60 patients with paroxysmal atrial fibrillation will receive radiofrequency ablation. Patients in each group will be randomly allocated into the statin treatment group and non-statin treatment group (allocation ratio, 1:1). Left atrial appendage flow velocity of all patients are measured by Transesophageal Echocardiography(TEE) 24 hours before the operation. Real-time ultrasound examinations of left atrial function are carried out for all patients before the operation and after the operation. Blood samples are extracted in all patients before the operation and after the operation. This study will clarify whether the application of statin drugs can improve postoperative left atrial function. This study will identify the time course and influence factors of left atrial recovery of atrial fibrillation after the operation to guide the time and the degree of anticoagulation and effectively prevent thromboembolic events. At the same time, biochemical indicators are detected to analyze which indicators are related to the postoperative recurrence of atrial fibrillation, the incidence of postoperative thrombosis and the recovery of postoperative left atrial function. Furthermore, this study will investigate whether the application of statin drugs can improve postoperative left atrial function by affecting these indicators.

Enrollment: 180 patients

Sex: All

Ages: Under 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All persistent or permanent AF patients with refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication.
• paroxysmal atrial fibrillation with refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication.
• age is <80 years

Exclusion criteria

• left ventricular dysfunction
• LA >50 mm
• atrial thrombosis
• valvular heart disease
• hyperthyroidism
• patients who underwent prosthetic heart valve replacement
• patients with previous history of atrial fibrillation ablation
• Hyperlipidemia
• pregnant women
• patients with existing liver and kidney disease
• malignant tumors
• hematological system diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

180 participants in 2 patient groups

atorvastatin group

Experimental group

Description:

atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.

Treatment:

Drug: atorvastatin group

non-atorvastatin group

Other group

Description:

atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..

Treatment:

Drug: non-atorvastatin group